SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : GTXi (GTXI)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: tuck who wrote (61)1/23/2009 9:45:34 AM
From: kenhott  Read Replies (1) of 85
 
Your goggle hit "Conclusions: These results indicate that toremifene is .... vascular toxicity ( QTc prolongation) in 3 (23%). of 13 men. Two (33%) of six men treated with . . ." was quoting a high dose (~200mg/m2/day) tamoxifen trial, 3 out of 13 men had grade 3 QTC. The EMEA looked at a placebo study with n=250 with 3 doses plus active moxifloxacin. They found similar QTc as moxifloxacin. The QTc was dose dependent. Dose for Fareston is 60mg/day vs. 80mg/day for PC side effect. The obvious question is risk vs. benefit in target, vs. options.

CC at noon.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News